264 related articles for article (PubMed ID: 30078506)
1. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
Wortman BG; Bosse T; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld H; van den Berg H; Slot A; De Winter KAJ; Verhoeven-Adema KW; Smit VTHBM; Creutzberg CL;
Gynecol Oncol; 2018 Oct; 151(1):69-75. PubMed ID: 30078506
[TBL] [Abstract][Full Text] [Related]
2. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
3. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
Creutzberg CL; van Stiphout RG; Nout RA; Lutgens LC; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):530-9. PubMed ID: 25680597
[TBL] [Abstract][Full Text] [Related]
4. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG; Creutzberg CL; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; van der Steen-Banasik EM; Mens JWM; Slot A; Kroese MCS; van Triest B; Nijman HW; Stelloo E; Bosse T; de Boer SM; van Putten WLJ; Smit VTHBM; Nout RA;
Br J Cancer; 2018 Oct; 119(9):1067-1074. PubMed ID: 30356126
[TBL] [Abstract][Full Text] [Related]
5. Patterns of care in women with high-intermediate risk endometrioid adenocarcinoma in the PORTEC-2 era: A SEER database analysis.
Zavitsanos PJ; Leonard KL
Brachytherapy; 2017; 16(1):109-115. PubMed ID: 27780688
[TBL] [Abstract][Full Text] [Related]
6. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
7. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.
Creutzberg CL; Nout RA; Lybeert ML; Wárlám-Rodenhuis CC; Jobsen JJ; Mens JW; Lutgens LC; Pras E; van de Poll-Franse LV; van Putten WL;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e631-8. PubMed ID: 21640520
[TBL] [Abstract][Full Text] [Related]
8. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
[TBL] [Abstract][Full Text] [Related]
9. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).
Mustea A; Koensgen D; Belau A; Sehouli J; Lichtenegger W; Schneidewind L; Sommer H; Markmann S; Scharf JP; Ehmke M; Ledwon P; Braicu I; Zygmunt M; Koehler G
Cancer Chemother Pharmacol; 2013 Nov; 72(5):975-83. PubMed ID: 23995698
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation.
McCloskey SA; Tchabo NE; Malhotra HK; Odunsi K; Rodabaugh K; Singhal P; Lele S; Jaggernauth W
Gynecol Oncol; 2010 Mar; 116(3):404-7. PubMed ID: 19944453
[TBL] [Abstract][Full Text] [Related]
12. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
13. Vaginal brachytherapy management of stage I and II endometrial cancer.
van den Heerik ASVM; Horeweg N; Creutzberg CL; Nout RA
Int J Gynecol Cancer; 2022 Mar; 32(3):304-310. PubMed ID: 35256416
[TBL] [Abstract][Full Text] [Related]
14. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study--quality-of-life analysis.
Sorbe BG; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Gynecol Cancer; 2012 Sep; 22(7):1281-8. PubMed ID: 22864336
[TBL] [Abstract][Full Text] [Related]
15. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
16. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.
Sorbe B; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1249-55. PubMed ID: 21676554
[TBL] [Abstract][Full Text] [Related]
17. Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.
Wortman BG; Astreinidou E; Laman MS; van der Steen-Banasik EM; Lutgens LCHW; Westerveld H; Koppe F; Slot A; van den Berg HA; Nowee ME; Bijmolt S; Stam TC; Zwanenburg AG; Mens JWM; Jürgenliemk-Schulz IM; Snyers A; Gillham CM; Weidner N; Kommoss S; Vandecasteele K; Tomancova V; Creutzberg CL; Nout RA;
Radiother Oncol; 2021 Feb; 155():160-166. PubMed ID: 33159971
[TBL] [Abstract][Full Text] [Related]
18. Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
Reboux PA; Azaïs H; Canova CH; Bendifallah S; Ouldamer L; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Collinet P; Bricou A; Huchon C; Daraï E; Ballester M; Lévêque J; Lavoué V; Koskas M; Uzan C; Canlorbe G
J Gynecol Oncol; 2019 Jul; 30(4):e53. PubMed ID: 31074238
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemoradiotherapy vs. radiotherapy alone in early-stage high-risk endometrial cancer: a systematic review and meta-analysis.
Jingjing H; Rui J; Hui P
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):833-840. PubMed ID: 30720192
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]